[Drug-resistant epilepsy in adults]

Area of Science:

• Neurology
• Epileptology

Context:

• Estimates of difficult-to-treat epilepsy patients range from 5-25% in literature.
• Lack of precise definitions for pharmacoresistance and refractory seizures contributes to variability.
• Seizure persistence does not always equate to true drug resistance; intermittent or variable frequencies occur.

Purpose:

• To clarify the definition and estimation of pharmacoresistant epilepsy.
• To identify predictive factors for intractable epilepsy.
• To emphasize the importance of early outcome evaluation in epilepsy management.

Summary:

• Pharmacoresistance in epilepsy is not a singular entity; definitions and estimations vary widely.
• Predictive factors for intractable epilepsy include seizure types, patient characteristics, epileptic syndrome, and antiepileptic drugs (AEDs).
• Early assessment of treatment response and epilepsy outcomes is vital for effective patient management.

Impact:

• Improved understanding of epilepsy pharmacoresistance can lead to more accurate patient stratification.
• Identification of predictive factors aids in earlier intervention and personalized treatment strategies.
• Early outcome evaluation facilitates timely adjustments in epilepsy care, potentially improving patient prognosis.